High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma
- 27 September 2018
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 118 (7) , 1115-1121
Abstract
Background: Survivin, one of the key regulators of mitosis and apoptosis, has long been well recognized to play important biological roles in many neoplasms, including pancreatic ductal adenocarcinoma (PDAC). However, its prognostic value in PDAC remains controversial.Patients and Methods: Nuclear expression of Survivin was detected, using tissue microarray‐based immunohistochemistry, in paired‐tumor and nontumor samples from 306 patients with radically resected PDAC. The staining H scores were further correlated with clinicopathologic features and disease‐specific survival (DSS).Results: Nuclear Survivin expression was much higher in tumor than in nontumor tissues (P < 0.001). No significant association between tumoral Survivin expression and clinicopathologic variables was found. For prognosis, high Survivin expression was associated with shortened DSS in all eligible patients and four subgroups, that is, male and nondiabetic patients as well as those with head‐located and G1‐2 tumors, shown by univariate analyses. In addition, a statistically marginal significance was revealed in eight subgroups. For the entire cohort and two subgroups, nuclear Survivin expression was also multivariate identified as an independent predictor for DSS. For patients with G1‐2 tumors, it was the single prognostic marker.Conclusion: Our data suggest an association between high nuclear Survivin expression and poor prognosis in PDAC. However, further confirmation might be necessary.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (CIFMS), China (2016-I2M-3-019)
- National High Technology Research and Development Program (863 Program), China (2014AA020609)
This publication has 35 references indexed in Scilit:
- miR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting SurvivinMolecular Medicine Reports, 2013
- Diagnostic, prognostic, and predictive biomarkers in pancreatic cancerJournal of Surgical Oncology, 2012
- Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinomaEuropean Journal of Surgical Oncology, 2012
- Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal AdenocarcinomaAmerican Journal of Surgical Pathology, 2012
- Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysisClinical Cancer Research, 2011
- Functional Role and Prognostic Significance of CD157 in Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 2010
- Nuclear Survivin Abrogates Multiple Cell Cycle Checkpoints and Enhances Viral OncolysisCancer Research, 2008
- siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine ChemosensitivityDigestive Diseases and Sciences, 2008
- The Effect of Apoptotic Activity, Survivin, Ki-67, and P-glycoprotein Expression on Prognosis in Pancreatic CarcinomaPancreas, 2005
- Survivin expression is a prognostic marker in pancreatic cancer patientsSurgery, 2004